Acadia Pharmaceuticals' CEO on Rebranding and AI Integration
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's recent rebrand and expansion into rare disease marketing, highlighting the role of AI in their strategy.
Neurological biotech Acadia Pharmaceuticals has rolled out a rebrand as it seeks to expand into the rare disease space, with AI playing a major role in their marketing strategy.
- Rebranding to expand into rare disease space
- AI integration in marketing strategy
- Challenges and benefits of marketing as a smaller biotech
Acadia CEO Catherine Owen Adams shares insights on the company's rebrand, AI use, and marketing approach.
Author's summary: Acadia Pharmaceuticals rebrands and expands into rare disease marketing with AI.
More News
- Eala falls to Mboko to exit Hong Kong Open
- Netanyahu Is Blowing Up the Gaza Ceasefire — and Trump Is the One Losing Face
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- Alphabet’s Financial Results Top Estimates As Cloud Grows 34%
- Feds Say Kat Abughazaleh “Impeded” ICE Agents. That Would Put Her on the Right Side of History.
- Stanley Gibbons Baldwin's Auction Highlights Preview: October 31, 2025